Nitastin (Simvastatin)

Simvastatin competitively inhibits HMG‑CoA reductase, the key enzyme in the hepatic synthesis of cholesterol. This inhibition reduces the amount of cholesterol produced by the liver, leading to an up‑regulation of LDL receptors and increased clearance of LDL particles from the bloodstream, thereby lowering plasma LDL‑cholesterol.

The appropriate dose of Nitastin is individualized by the prescribing clinician based on the patient’s baseline lipid profile, cardiovascular risk, age, renal and hepatic function, and any concomitant medications. No fixed regimen is provided here; the prescriber sets the dose according to clinical guidelines.

Safety of simvastatin in pregnancy and lactation has not been established, and the drug is generally contraindicated for these populations. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative lipid‑lowering strategies with their healthcare provider.

To order Nitastin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nitastin (simvastatin) is a moderately potent statin with a well‑characterised efficacy and safety profile. Compared with higher‑potency agents such as rosuvastatin or atorvastatin, simvastatin may require higher doses to achieve similar LDL‑cholesterol reductions, but it is often chosen for its extensive clinical experience and cost‑effectiveness.

Nitastin tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral dosage form.

Nitastin is taken orally, usually once daily in the evening, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and can be taken with or without food, unless the prescribing information advises otherwise.

The most serious adverse events linked to Nitastin include rhabdomyolysis, a severe form of muscle breakdown that can lead to kidney failure, and acute liver injury manifested by marked elevations in liver enzymes or jaundice. Prompt medical attention is required if patients experience unexplained muscle pain, weakness, or signs of liver dysfunction.

Nitastin should be avoided in patients with active liver disease, unexplained persistent elevations of transaminases, known hypersensitivity to simvastatin, or those who are pregnant or breastfeeding. It is also contraindicated when used together with strong CYP3A4 inhibitors such as certain antifungals or macrolide antibiotics.